Steel Grove Capital Advisors LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 680 shares of the company's stock, valued at approximately $525,000.
A number of other large investors have also bought and sold shares of the stock. Highline Wealth Partners LLC grew its position in Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. lifted its stake in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $48,000. Compass Financial Services Inc bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $50,000. Finally, Fiduciary Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $58,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on LLY shares. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research report on Tuesday. They issued an "overweight" rating and a $975.00 price target for the company. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their target price for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,017.00.
Check Out Our Latest Stock Report on Eli Lilly and Company
Insider Buying and Selling at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company's stock.
Eli Lilly and Company Stock Performance
Eli Lilly and Company stock traded up $25.21 during trading on Friday, hitting $884.94. The stock had a trading volume of 3,395,903 shares, compared to its average volume of 3,435,687. The stock's 50 day moving average is $827.14 and its two-hundred day moving average is $818.81. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market cap of $839.07 billion, a price-to-earnings ratio of 75.57, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
